Sector News

Former Valeant CFO Schiller to step in for hospitalized CEO Pearson

January 6, 2016
Life sciences

Last week, Valeant CEO J. Michael Pearson, in the hospital with severe pneumonia, took a medical leave of absence. And now, the company is putting a new chief in his place.

Former Valeant CFO and board member Howard Schiller will step in for Pearson on an interim basis, effective immediately, Valeant said Wednesday morning. Robert Ingram, the company’s lead independent director, will serve as interim chairman.

“Howard’s performance as Valeant’s CFO, as well as his deep understanding of Valeant’s operations, are excellent and we are grateful that he has agreed to take on this role. The board will continue to work closely with Howard and the other members of the senior management team to implement Valeant’s strategy successfully in Mike’s absence,” Ingram said in a statement, noting that the timing of Pearson’s recovery and return “remains uncertain.”

Schiller, who served as Valeant’s CFO from December 2011 through June 2015, will step in for the three-man Office of the Chief Executive Officer–comprising General Counsel Robert Chai-Onn, Company Group Chairman Ari Kellen and current CFO Robert Rosiello–that’s been running the show in Pearson’s stead since Dec. 28.

The move marks one of many recent changes for the Quebec-based drugmaker, which has floundered lately amid political scrutiny over its pricing practices and allegations that it used its relationship with specialty pharmacy Philidor to inflate its top line. To fill the void after cutting ties with Philidor, the company announced a pricing and distribution deal with Walgreens last month–as well as plans to scrap “virtually all” of its planned price hikes for this year.

But despite the beating the company’s stock has taken throughout the course of the controversy, Valeant’s board has continued to back Pearson, who has remade the company into a skincare and eye-care-focused M&A machine since taking the helm in 2008.

“Mike remains focused on running the business and has been meeting with physicians, partners, and other stakeholders,” company spokeswoman Laurie Little told Bloomberg by email in November. “Despite recent market volatility that has impacted our stock price, Valeant’s core business remains strong and is well positioned for growth.”

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach